Context Therapeutics is expected to report a consensus EPS of -$0.10 on zero revenue for the second quarter, with the current stock price of $0.62 reflecting significant potential upside to the average analyst target of $6.17.
Investors are primarily focused on clinical updates for CTIM-76, the company’s lead Claudin 6-targeting bispecific antibody, following encouraging interim Phase 1 data released in June.
Management is anticipated to detail the transition to every-three-week (Q3W) dosing for CTIM-76 and the progress of trial expansion cohorts across solid tumor indications.
Furthermore, updates on the company’s cash runway—currently projected to last into mid-2027—will be vital to ensuring the long-term funding of its bispecific antibody pipeline.